By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Delenex Therapeutics AG 

Wagistrasse 23

Zurich-Schlieren     CH-8952  Switzerland
Phone: +41-44-7305180 Fax: +41-44-7305181




Company News
Delenex Therapeutics Extends Scientific Advisory Board 7/6/2015 10:25:22 AM
Delenex Therapeutics Release: In Vitro And In Vivo Efficacy Of DLX1008, A Monovalent Antibody Fragment With Low Picomolar Affinity To VEGF-A, In Human Glioma Models 6/9/2015 9:10:52 AM
Delenex Therapeutics Release: Anti-Tumor Activity Of DLX1008, An Anti-VEGF-A Antibody Fragment With Low Picomolar Affinity, In An In Vivo Model Of Kaposi Sarcoma 5/28/2015 2:25:05 PM
Delenex Therapeutics Release: New Clinical Data Show Biologic Activity Of DLX105 Upon Topical Application Onto Psoriatic Skin 9/11/2014 10:01:23 AM
Delenex Therapeutics Release: New Clinical Data On The Topical Application Of PENTRA®Bodies To Be Presented At The 44th Annual ESDR Meeting 9/2/2014 2:26:50 PM
Jens Hennecke Joins Delenex Therapeutics As Business and Corporate Development Advisor 11/12/2013 11:11:08 AM
Delenex Therapeutics Completes its Management Team 9/1/2011 8:20:51 AM
Delenex Therapeutics Appoints Eric de La Fortelle as CEO and Jakob Schlapbach as CFO 2/1/2011 6:32:07 AM